Rebuilding Missing Muscle

An acellular matrix can help guide stem cells to injury sites and regrow muscles in both mice and humans, a study finds.

Apr 30, 2014
Rina Shaikh-Lesko

WIKIMEDIA, NEPHRONResearchers have refined a method for regenerating large amounts of muscle lost after injury using material from pig bladders, according to a study published today (April 30) in Science Translational Medicine. A team from the University of Pittsburgh, led by Stephen Badylak, implanted extracelluar matrix, denuded of cells, from the lining of pig bladders, first into mice and eventually into five male patients.

“It’s a good correlation of a treatment of a muscle volumetric defect—in people—with an effort to understand the actual effect on muscle repair that’s occurring,” said Jason Pomerantz, who focuses on tissue regeneration at the University of California, San Francisco, but was not involved in the study.

The male patients all had traumatic muscle injuries—three from military incidents, two from skiing accidents—large enough to be classified as volumetric muscle loss. Muscle tissue is adept at repairing itself, but if a large enough chunk is lost, the remaining muscle cannot replenish what’s missing and usually fills in the gaps with scar tissue. Many researchers are investigating how to use stem cells or progenitor muscle cells to repair muscle injuries, but even the most successful to date have only managed to generate small volumes of cells, all of which are not yet nearly large enough to replace the tissue lost in volumetric muscle loss. Their efforts have been stymied by immunogenic host responses to the stem cells, inefficient methods of delivery, and cell death after transplantation.

But pig bladder lining has long been used in human reconstructive surgeries. It is often used as a passive supportive material in repairs of herniated abdominal walls, breast reconstruction, and other applications. So the Pittsburgh researchers decided to test the substrate. The team removed all the cells from the bladder lining, leaving behind only an extracellular protein matrix. Badylak noted that the most immunogenic molecules are part of cellular membranes and by removing all the cellular material—the most likely reason for a patient’s body to reject an implant—the risk of rejection decreased.

With muscle-regenerating scaffolds in hand, the researchers first conducted preclinical trials in mice that had sections of their quadriceps removed. Two weeks after implantation, the researchers noticed that perivascular stem cells moved out of their usual niche near blood vessels and into the implanted extracellular matrix, which was degrading over time. They also saw signs of muscle regeneration up to six months post-implantation. The regenerated muscle in treated mice was eventually innervated and vascularized. In untreated mice, perivascular stem cells rarely left their niches and there was no evidence of muscle repair at the six-month mark.

The researchers speculated that as the extracellular matrix degrades over time within the body, it releases proteins that attract muscle-building machinery, including perivascular stem cells. It appears that instead of a destructive immune response, the extracellular matrix induces a positive immune response. 

“These degraded materials, these peptides that are released, serve as a homing device for the body's own stem cells [which] are recruited into the site of injury and then are available to differentiate into a site-appropriate of tissue”, Badylak said.

The team then moved on to clinical trials, testing its approach on patients who had all had at least six months of physical therapy without any signs of progress. Each man had been injured between 13 months and seven years before the surgeries and had lost most—58 percent to 90 percent—of the muscle of interest. The patients underwent rigorous physical therapy for 12 weeks to 16 weeks. When they plateaued in their progress, the researchers removed the built-up scar tissue and implanted the pig bladder extracellular matrix. Within a few days of surgery, the patients were put back on a physical therapy regimen, which they continued for up to 25 weeks. Clinicians measured their muscle growth using CT scans and MRIs, as well as biopsies. All the patients experienced muscle regrowth and improved abilities carrying out day-to-day tasks. Three of the five patients met all the requirements the researchers had set for successful surgeries. The two remaining patients did improve in most areas of function, but fell short of the cut-off.

The researchers had previously shown that lack of mechanistic stress on the surgery site leads to less muscle regeneration.

“The sheer stress and stretch applied to these cells release what we call paracrine factors, which means the cells talk to each other, and recruit progenitor cells to that area, and kind of turn them on,” said study coauthor Brian Sicari.

“It’s obviously disappointing they weren’t able to see a consistent improvement, but expected considering the conditions” of the small clinical trial, said Dawn Cornelison from the University of Missouri, who was not involved in the research. Cornelison expressed interest in whether the technique could be readily reproduced in the lab to address basic research questions about the cellular mechanisms that underlie the recoveries.

The researchers are now continuing to perform case studies of patients with volumetric muscle loss and trying to better understand the cellular mechanisms behind this process.

B.M. Sicari et al., "An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss,” Science Translational Medicine, doi:10.1126/scitranslmed.3008085, 2014.  

November 2018

Intelligent Science

Wrapping our heads around human smarts


Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.